{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:31:04Z","timestamp":1791325864399,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.bulcan.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T08:01:32Z","timestamp":1681804892000},"page":"605-615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact"],"prefix":"10.1016","volume":"110","author":[{"given":"Cl\u00e9mentine","family":"Jankowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elo\u00efse","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Beltjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Coutant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2023.03.009_bib0195","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2008.15.0243","article-title":"Locally advanced and inflammatory breast cancer","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2023.03.009_bib0200","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1016\/j.bulcan.2023.03.009_bib0205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.009_bib0210","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","article-title":"Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy","volume":"17","author":"Kuerer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.009_bib0215","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdu118","article-title":"Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\/BIG 1-00 phase III trial","volume":"25","author":"Bonnefoi","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.009_bib0220","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.03.009_bib0225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.009_bib0230","unstructured":"http:\/\/oncologik.fr\/referentiels\/rrc\/sein-principes-de-prise-en-charge."},{"issue":"13","key":"10.1016\/j.bulcan.2023.03.009_bib0235","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.bulcan.2023.03.009_bib0240","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2023.03.009_bib0245","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.bulcan.2023.03.009_bib0250","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.21.00934","article-title":"Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline","volume":"39","author":"Brackstone","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2023.03.009_bib0255","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","article-title":"Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with slnd alone in the american college of surgeons oncology group trial Z0011","volume":"25","author":"Lucci","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9712","key":"10.1016\/j.bulcan.2023.03.009_bib0260","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"9897","key":"10.1016\/j.bulcan.2023.03.009_bib0265","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"issue":"10191","key":"10.1016\/j.bulcan.2023.03.009_bib0270","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bulcan.2023.03.009_bib0275","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2023.03.009_bib0280","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.canrad.2014.02.004","article-title":"Efficacit\u00e9 et s\u00e9curit\u00e9 de la technique de radioth\u00e9rapie mammaire avec compl\u00e9ment d\u2019irradiation concomitant\u00a0: analyse de 121 cas trait\u00e9s \u00e0 l\u2019institut de canc\u00e9rologie de Lorraine","volume":"18","author":"Renoult","year":"2014","journal-title":"Cancer\/Radiotherapie"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.009_bib0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.009_bib0290","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1245\/s10434-019-07635-x","article-title":"Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials","volume":"26","author":"Krug","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"9804","key":"10.1016\/j.bulcan.2023.03.009_bib0295","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.009_bib0300","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annpat.2019.04.004","article-title":"Recommandations du GEFPICS pour la prise en charge des pr\u00e9l\u00e8vements dans le cadre du traitement n\u00e9oadjuvant du cancer du sein","volume":"39","author":"Maran-Gonzalez","year":"2019","journal-title":"Ann Pathol"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.009_bib0305","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","article-title":"Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18","volume":"15","author":"Fisher","year":"1997","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.03.009_bib0310","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","article-title":"Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Wong","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.009_bib0315","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/cncr.25152","article-title":"Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer","volume":"116","author":"Dominici","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.009_bib0320","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/jamaoncol.2015.4935","article-title":"Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy","volume":"2","author":"Mougalian","year":"2016","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.009_bib0325","doi-asserted-by":"crossref","first-page":"e210891","DOI":"10.1001\/jamasurg.2021.0891","article-title":"Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis","volume":"156","author":"Samiei","year":"2021","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.009_bib0330","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","article-title":"The clinical significance of breast-only and node-only pathologic complete response (pCR) After neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the national cancer data base (NCDB)","volume":"268","author":"Fayanju","year":"2018","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.bulcan.2023.03.009_bib0335","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.009_bib0340","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2023.03.009_bib0345","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.009_bib0350","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.03.009_bib0355","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04622319."},{"issue":"25","key":"10.1016\/j.bulcan.2023.03.009_bib0360","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1\u00a0\u2013\u00a0or BRCA2 -mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.009_bib0365","first-page":"522","article-title":"Ganglion sentinelle et cancer du sein\u00a0: o\u00f9 en est-on en 2019\u00a0?","volume":"47","author":"Zeitoun","year":"2019","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.009_bib0370","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of ganglion sentinelle et chimiotherapie neoadjuvante, a French prospective multicentric study","volume":"27","author":"Classe","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2023.03.009_bib0375","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.03.009_bib0380","unstructured":"https:\/\/www.clinicaltrials. gov\/ct2\/show\/NCT03630913."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:49Z","timestamp":1757792269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0007455123001534"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}